Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.
Anti-cancer CAR-T therapy reengineers T cells to kill tumors – and researchers are expanding the limited types of cancer it can target
Gregory Allen, Assistant Professor of Medicine, University of California, San Francisco